This year has included many twists and turns for IP stakeholders, particularly on the patent side. Most recently, the Federal Circuit’s decision in Arthrex has called into question the constitutionality of Patent Trial and Appeal Board decisions, and perhaps the Board itself. Elsewhere, Congress has been—unsuccessfully—attempting to step in and clarify U.S. patent law since early in the year, while the courts have continued to muddy the waters of patent eligibility law. The Federal Trade Commission’s case against Qualcomm, and Judge Lucy Koh’s decision in the case, have further called into question the United States’ ability to compete on the innovation front going forward. And yet, there have been some wins in other areas this year, including at the U.S. Patent and Trademark Office (USPTO), and there remain many reasons to be hopeful about the year ahead. IPWatchdog asked some IP experts to share what they have to be thankful for on the IP front this Thanksgiving, despite all the uncertainty. Hopefully, as those of you who celebrate the holiday enjoy your Thanksgiving dinners, these sentiments will inspire you to be thankful too.
- Computer Law
- Fair Use
- First Sale Doctrine
- The Top Five European IP Developments of 2019—and Five to Watch for 2020
- The Most Iconic (and Patented) Toys and Games of All Time
- Other Barks & Bites, Friday, December 6: Lawmakers Concerned with Copyright Restatement, USPTO Pushed to Keep SEP Injunction Policy, Qualcomm Pushes Back on Koh at Ninth Circuit
- Other Barks & Bites for Friday, November 29: China Pledges ‘Social Satisfaction’ on IP Protection and Nominates Candidate to Head WIPO
- This Thanksgiving: What Is the IP Community Thankful For?
- VirnetX Urges SCOTUS to End Apple Gamesmanship in Decade-Long Patent Battle
- Trademark Litigation Review—What Happened in 2019 and What to Watch This Year
- Eight Tips to Get Your Patent Approved at the EPO
- Trade Secrets Review: Key 2019 Decisions and Trends (Part I)
- Responding to Criticism of ‘State Pharmaceutical Importation Programs Threaten Patients and Innovation’